Sigachi's Hyderabad Leap: ₹8.3 Cr Investment Fuels Pharma R&D

Sigachi Industries has inaugurated its cutting-edge Research & Development (R&D) Center in Hyderabad, marking a significant step forward in its innovation strategy. Purpose-built to fast-track the development of critical Active Pharmaceutical Ingredients (APIs), the facility also strengthens the company’s in-house analytical and regulatory capabilities.

Equipped with state-of-the-art infrastructure, the Hyderabad R&D Center integrates synthesis, analytical operations, and regulatory support to streamline API development and ensure global compliance. Sigachi is investing up to ₹8.3 crore (approximately USD 1 million) in this initiative to expand its API pipeline and develop complex intermediates. The center will also align with strategic therapeutic areas, allowing the company to focus R&D efforts where they are most impactful.

“This R&D Center reflects our commitment to scientific excellence and continuous innovation,” said a company spokesperson. “It will play a pivotal role in advancing our product pipeline and strengthening our ability to deliver high-quality solutions to global partners.”

Sigachi Industries' broad portfolio spans APIs, intermediates, pharmaceutical excipients, vitamin-mineral premixes, and operations & maintenance (O&M) services, produced across its five manufacturing units located in Telangana, Gujarat, and Karnataka.

News by Rahul Yelligetti.